Literature DB >> 15029263

Modeling of main characteristics of bullous pemphigoid antigen-2 (BPAG2) peptide structure in serological recognition by autoantibodies.

József Pál1, Ilona Marczinovits, Ferenc Hudecz, Gábor K Tóth, Gábor Mezõ, János Molnár, Péter Németh.   

Abstract

The serum level of autoantibodies against autoantigens of the bullous pemphigoid peptides 1 and 2 (BPAG1 and BPAG2) is a relevant diagnostic marker. Twelve representative sera of BP were tested against the RSILPYGDSMDRIEKDRLQMAP amino acid sequence that is an epitope fragment of the NC16A domain of BPAG2 (AC Q02802; 507-528) to find the most suitable antigenic form for specific detection of autoantibodies of BP patients' sera by quantitative ELISA system. The antigenic epitope sequence was presented as an antigen in a carrier free form of dimeric peptide (BP22), dimeric peptide fused to glutathione S-transferase (GST-BP22) or dimeric peptide chemically conjugated to polyLys(Ser-DL-Alam) (SAK-BP22). The intensity of ELISA reaction was highest against the recombinant fusion antigen GSTBP22; the chemically conjugated SAK-BP22 performed less well than the free dimeric form of the peptide. In the case of the GST-BP22 antigen, the (GST-BP22)-(GST)492nm optical density values were determined. There was no significant difference between the mean ODs of the GST-BP22 and the SAK-BP22 (0.888 vs. 0.892, p= 0.9726). Conjugating the epitope peptide with the synthetic carrier SAK was advantageous, as it abrogated cross-reactivity with GST carrier protein. Consequently, the SAKBP22 conjugate appears to be the most reliable assay component, avoiding cross-reactivity with GST and simplifying the detection and evaluation of BP autoantibodies in routine ELISA diagnostic system.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15029263     DOI: 10.1007/BF02893410

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  12 in total

1.  IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in Bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity.

Authors:  R Döpp; E Schmidt; I Chimanovitch; M Leverkus; E B Bröcker; D Zillikens
Journal:  J Am Acad Dermatol       Date:  2000-04       Impact factor: 11.527

2.  Conformational consequences of coupling bullous pemphigoid antigenic peptides to glutathione-S-transferase and their diagnostic significance.

Authors:  I Laczkó; E Vass; G K Tóth; I Marczinovits; M Kiss; S Husz; J Molnár
Journal:  J Pept Sci       Date:  2000-08       Impact factor: 1.905

3.  Tight clustering of extracellular BP180 epitopes recognized by bullous pemphigoid autoantibodies.

Authors:  D Zillikens; P A Rose; S D Balding; Z Liu; M Olague-Marchan; L A Diaz; G J Giudice
Journal:  J Invest Dermatol       Date:  1997-10       Impact factor: 8.551

4.  A highly sensitive enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid.

Authors:  D Zillikens; J M Mascaro; P A Rose; Z Liu; S M Ewing; F Caux; R G Hoffmann; L A Diaz; G J Giudice
Journal:  J Invest Dermatol       Date:  1997-11       Impact factor: 8.551

5.  Carrier design: new generation of polycationic branched polypeptides containing OH groups with prolonged blood survival and diminished in vitro cytotoxicity.

Authors:  F Hudecz; M V Pimm; E Rajnavölgyi; G Mezo; A Fabra; D Gaál; A L Kovács; A Horváth; M Szekerke
Journal:  Bioconjug Chem       Date:  1999 Sep-Oct       Impact factor: 4.774

6.  Anti-SLA seropositive autoimmune hepatitis sera recognize distinct subunits of glutathione S-transferase: high prevalence of the Ya autoantigen.

Authors:  Jozefa Wesierska-Gadek; Herbert Lindner; Eva Hitchman; Bettina Sarg; Edward Penner
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  2002-05       Impact factor: 1.770

Review 7.  Synthetic peptides in biochemical research.

Authors:  D C Hancock; N J O'Reilly; G I Evan
Journal:  Mol Biotechnol       Date:  1995-08       Impact factor: 2.695

8.  Development of a system for detection of circulating antibodies against hemidesmosomal proteins in patients with bullous pemphigoid.

Authors:  S Husz; M Kiss; K Molnár; I Marczinovits; J Molnár; G K Tóth; A Dobozy
Journal:  Arch Dermatol Res       Date:  2000-05       Impact factor: 3.017

9.  Immunoreactivity of bullous pemphigoid (BP) autoantibodies against the NC16A and C-terminal domains of the 180 kDa BP antigen (BP180): immunoblot analysis and enzyme-linked immunosorbent assay using BP180 recombinant proteins.

Authors:  C Nakatani; T Muramatsu; T Shirai
Journal:  Br J Dermatol       Date:  1998-09       Impact factor: 9.302

10.  Autoimmune sera react with multiple epitopes on recombinant 52 and 60 kDa Ro(SSA) proteins.

Authors:  D P McCauliffe; H Yin; L X Wang; L Lucas
Journal:  J Rheumatol       Date:  1994-06       Impact factor: 4.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.